✦ LIBER ✦

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4

✍ Scribed by A.E. Pedersen; S. Buus; M.H. Claesson

Book ID: 116333755
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 165 KB
Volume: 235
Category: Article
ISSN: 0304-3835
DOI: 10.1016/j.canlet.2005.04.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical phase I study of elpamotide, a

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

✍ Okamoto, Isamu; Arao, Tokuzo; Miyazaki, Masaki; Satoh, Taroh; Okamoto, Kunio; Ts 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

Combination of low vascular endothelial

Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer

✍ Tom Donnem; Khalid Al-Shibli; Sigve Andersen; Samer Al-Saad; Lill-Tove Busund; R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB 👁 1 views

1788 EXPRESSION LEVEL OF VASCULAR ENDOTH

1788 EXPRESSION LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 IN RADICAL NEPHRECTOMY SPECIMENS AS A PROGNOSTIC PREDICTOR IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH SUNITINIB

✍ Terakawa, Tomoaki; Miyake, Hideaki; Kusuda, Yuji; Fujisawa, Masato 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 119 KB

P040 Tivozanib pharmacokinetic (PK)/phar

P040 Tivozanib pharmacokinetic (PK)/pharmacodynamic (PD) analysis of blood pressure (BP) and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)

✍ Nosov, D.A.; Motzer, R.J.; Loewy, J.; Hodge, L.; Esteves, B.; Berkenblit, A.; Yi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 260 KB